Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 16/20 | 0.72 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 7/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003158 | 0.86 | S1PR3 (0.57) | S1PR3 | |
| SCHEMBL3997726 | 0.86 | S1PR3 (0.56) | S1PR3PTGDR2 | |
| SCHEMBL805645 | 0.85 | S1PR3 (0.94) | S1PR3S1PR2S1PR1LPAR2S1PR4 | |
| SCHEMBL803571 | 0.84 | S1PR3 (1.00) | S1PR3PTGDR2 | |
| SCHEMBL291259 | 0.84 | S1PR3 (1.00) | S1PR3S1PR2S1PR1LPAR2S1PR4 | |
| SCHEMBL3996446 | 0.82 | S1PR3 (0.52) | S1PR3PTGDR2 | |
| SCHEMBL805685 | 0.82 | S1PR3 (1.00) | S1PR3PTGDR2S1PR2S1PR1LPAR2 | |
| SCHEMBL36337 | 0.80 | S1PR3 (0.87) | S1PR3S1PR2S1PR1LPAR2S1PR4 | |
| SCHEMBL2837203 | 0.80 | S1PR3 (0.60) | S1PR3PTGDR2 | |
| SCHEMBL291260 | 0.78 | S1PR3 (0.61) | S1PR3PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | DONELLO JOHN E | 2011-01-13 | — | — | US | disclosed |
| EP-2066633-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008030843-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030843-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | S1PR3, LPAR3, S1PR2 | S1PR3 1/4885PTGDR2 198/4885S1PR2 3/4885 |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885PTGDR2 295/4885S1PR2 3/4885 |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885PTGDR2 186/4885S1PR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.